Electrophysiologic and Hemodynamic Effects of a Single Oral Dose of Pilsicainide Hydrochloride, a New Class 1c Antiarrhythmic Agent
- 1 January 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 31 (1) , 157-164
- https://doi.org/10.1097/00005344-199801000-00021
Abstract
To establish the clinical efficacy of pilsicainide, we evaluated its electrophysiologic and hemodynamic effects after a single oral administration to 18 patients with documented supraventricular tachycardia (SVT). To determine the minimal effective blood level, changes in efficacy with time were evaluated by serial reinduction studies with venous blood sampling for measurement of the plasma pilsicainide level. Sixty minutes after administration of a single oral dose of pilsicainide, the sinoatrial conduction time, AH and HV intervals, and the effective refractory period of the right ventricle were prolonged. Ventriculoatrial conduction was blocked in 11 patients [nine of 12 via accessory pathway and two of six via the atrioventricular (AV) node], resulting in the suppression of SVT induction in nine of 13 patients. Pilsicainide increased the heart rate and mean pulmonary arterial pressure and decreased the stroke volume index at 60 min. PQ interval, QRS width, and QTc were significantly prolonged after pilsicainide, and the percentage prolongations of the PQ interval were well correlated with the plasma pilsicainide levels. The plasma level effective for suppression of SVT was considered to be >0.5 μg/ml. We concluded that a single oral administration of pilsicainide is well tolerated and effective in suppressing SVT.Keywords
This publication has 26 references indexed in Scilit:
- Effects of Pilsicainide on the Atrial Fibrillation Threshold in Guinea Kg Atria. A Comparative Study with Disopyramide, Lidocaine and Flecainide.Japanese Heart Journal, 1993
- Effects of SUN-1165, N-(2,6-Dimethylphenyl)-8-Pyrrolizidine Acetamide Hydrochloride Hemihydrate, a New Class I Antiarrhythmic Drug, on Ventricular Arrhythmias, Intraventricular Conduction, and the Refractory Period in Canine Myocardial InfarctionJournal of Cardiovascular Pharmacology, 1992
- Suppressive effect of SUN1165 on supraventricular tachycardiaAmerican Heart Journal, 1991
- Effect of SUN 1165, a New Potent Antiarrhythmic Agent, on the Kinetics of Rate-Dependent Block of Na Channels and Ventricular Conduction of ExtrasystolesJournal of Cardiovascular Pharmacology, 1988
- Mechanism of inhibition by SUN 1165, a new Na channel blocking antiarrhythmic agent, of cardiac glycoside-induced triggered activityEuropean Journal of Pharmacology, 1988
- Sun 1165: A new antiarrhythmic na current blocker in ventricular myocytes of guinea-pigComparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1987
- Electrophysiological Actions of N-(2,6-Dimethylphenyl)-8-Pyrrolizidine-Acetamide Hydrochoride Hemihydrate (SUN 1165), a New Antiarrhythmic AgentJournal of Cardiovascular Pharmacology, 1986
- New antiarrhythmic agents. N-Aryl-8-pyrrolizidinealkanamidesJournal of Medicinal Chemistry, 1985
- Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: A comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165Heart and Vessels, 1985
- Premature Atrial Stimulation as a Key to the Understanding of Sinoatrial Conduction in ManCirculation, 1973